Core Viewpoint - The company's stock price has declined significantly, reflecting challenges in its core business operations and ongoing legal issues [1] Financial Performance - The company reported a revenue of 151 million yuan for the first half of 2025, a year-on-year decrease of 5.77% [1] - The net profit attributable to shareholders was 2.25 million yuan, down 30.54% compared to the previous year [1] Business Operations - The health supplement raw material business has experienced a decline due to intensified industry competition [1] - The medical and nursing business faced interruptions in operational income due to management agreement disputes, with related litigation currently in the second instance [1] Market Activity - The stock price was reported at 8.33 yuan, down 6.19% from the previous trading day, with a trading volume of 172 million yuan [1] - Institutional investors held a total of 58.7% of the shares as of July 30, a decrease of 0.57 percentage points from the previous quarter [1] Capital Flow - On July 31, the net outflow of main funds was 8.32 million yuan, accounting for 0.13% of the circulating market value [2]